Medpace (MEDP) vs NRC Health (NRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NRC Health (NRC) has outperformed Medpace (MEDP) over the past year, gaining 71.3% versus a gain of 13.5%. Over five years, MEDP leads with a +222.2% price change compared with -52.4% for NRC. Medpace is the larger company by market cap ($17.11 billion vs $442.6 million), about 38.7 times the size.
On valuation, NRC Health trades at a lower forward P/E (19.1x vs 31.7x for Medpace). NRC Health pays a dividend yielding 3.00%, while Medpace does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MEDP | NRC |
|---|---|---|
| Share price | $613.15 | $20.01 |
| Market cap | $17.11B | $442.61M |
| 1-day change | +1.73% | -2.01% |
| YTD return | +7.31% | +8.79% |
| 1-year return | +13.50% | +71.31% |
| 5-year return | +222.16% | -52.38% |
| P/E ratio (TTM) | 36.00 | 83.38 |
| Forward P/E | 31.74 | 19.06 |
| EPS (TTM) | $17.03 | $0.24 |
| Dividend yield | 0.00% | 3.00% |
| Annual dividend | $0.00 | $0.60 |
| Revenue (latest FY) | $2.53B | — |
| Revenue growth (YoY) | +19.97% | — |
| Net income (latest FY) | $451.12M | — |
| Operating margin | 21.14% | — |
| Net margin | 17.83% | — |
| 52-week high | $677.90 | $23.68 |
| 52-week low | $373.00 | $11.01 |
| Distance from 52-week high | -9.55% | -15.50% |
| Analyst consensus | hold | none |
| Avg. price target upside | -3.47% | +29.94% |
| Average volume | 272.38K | 115.97K |
| Shares outstanding | 27.91M | 22.12M |
| Employees | 6,500 | 357 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medpace is about 38.7 times larger than NRC Health by market value ($17.11B vs $442.61M).
- NRC has outperformed MEDP by 57.8 percentage points over the past year.
- NRC Health trades at a higher earnings multiple (83.4x vs 36.0x trailing P/E).
- NRC Health offers a meaningfully higher dividend yield (3.00% vs 0.00%).
About Medpace
MEDP stock →Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 6,500 employees
About NRC Health
NRC stock →NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 357 employees
MEDP vs NRC FAQ
Which is bigger, Medpace or NRC Health?
Medpace (MEDP) is larger, with a market capitalization of $17.11B compared with $442.61M for NRC Health (NRC).
Which stock has performed better over the past year, MEDP or NRC?
NRC returned +71.31% over the past 12 months, compared with +13.50% for MEDP (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, MEDP or NRC?
MEDP has the lower trailing P/E at 36.0, versus 83.4 for NRC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Medpace or NRC Health?
NRC Health pays a dividend yielding 3.00%, while Medpace does not currently pay a regular dividend.
Are Medpace and NRC Health in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.